Literature DB >> 24765712

Reliability of Autism-Tics, AD/HD, and other Comorbidities (A-TAC) inventory in a test-retest design.

Tomas Larson, Nóra Kerekes, Eva Norén Selinus, Paul Lichtenstein, Clara Hellner Gumpert, Henrik Anckarsäter, Thomas Nilsson, Sebastian Lundström.   

Abstract

The Autism-Tics, AD/HD, and other Comorbidities (A-TAC) inventory is used in epidemiological research to assess neurodevelopmental problems and coexisting conditions. Although the A-TAC has been applied in various populations, data on retest reliability are limited. The objective of the present study was to present additional reliability data. The A-TAC was administered by lay assessors and was completed on two occasions by parents of 400 individual twins, with an average interval of 70 days between test sessions. Intra- and inter-rater reliability were analysed with intraclass correlations and Cohen's kappa. A-TAC showed excellent test-retest intraclass correlations for both autism spectrum disorder and attention deficit hyperactivity disorder (each at .84). Most modules in the A-TAC had intra- and inter-rater reliability intraclass correlation coefficients of > or = .60. Cohen's kappa indi- cated acceptable reliability. The current study provides statistical evidence that the A-TAC yields good test-retest reliability in a population-based cohort of children.

Entities:  

Mesh:

Year:  2014        PMID: 24765712     DOI: 10.2466/03.15.PR0.114k10w1

Source DB:  PubMed          Journal:  Psychol Rep        ISSN: 0033-2941


  8 in total

Review 1.  Systematic review of severity scales and screening instruments for tics: Critique and recommendations.

Authors:  Davide Martino; Tamara M Pringsheim; Andrea E Cavanna; Carlo Colosimo; Andreas Hartmann; James F Leckman; Sheng Luo; Alexander Munchau; Christopher G Goetz; Glenn T Stebbins; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2017-01-10       Impact factor: 10.338

2.  Preschool to School in Autism: Neuropsychiatric Problems 8 Years After Diagnosis at 3 Years of Age.

Authors:  M Barnevik Olsson; S Lundström; J Westerlund; M B Giacobini; C Gillberg; E Fernell
Journal:  J Autism Dev Disord       Date:  2016-08

3.  Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples.

Authors:  Sebastian Lundström; Abraham Reichenberg; Henrik Anckarsäter; Paul Lichtenstein; Christopher Gillberg
Journal:  BMJ       Date:  2015-04-28

4.  Subthreshold and threshold attention deficit hyperactivity disorder symptoms in childhood: psychosocial outcomes in adolescence in boys and girls.

Authors:  E Norén Selinus; Y Molero; P Lichtenstein; H Anckarsäter; S Lundström; M Bottai; C Hellner Gumpert
Journal:  Acta Psychiatr Scand       Date:  2016-10-07       Impact factor: 6.392

5.  The coexistence of psychiatric and gastrointestinal problems in children with restrictive eating in a nationwide Swedish twin study.

Authors:  Jakob Täljemark; Maria Råstam; Paul Lichtenstein; Henrik Anckarsäter; Nóra Kerekes
Journal:  J Eat Disord       Date:  2017-08-21

6.  The development of a brief screener for autism using item response theory.

Authors:  Caroline Mårland; Gitta Lubke; Alessio Degl'Innocenti; Maria Råstam; Christopher Gillberg; Thomas Nilsson; Sebastian Lundström
Journal:  BMC Psychiatry       Date:  2019-11-04       Impact factor: 3.630

7.  The Autism-Tics, ADHD and other Comorbidities inventory (A-TAC): previous and predictive validity.

Authors:  Caroline Mårland; Paul Lichtenstein; Alessio Degl'Innocenti; Tomas Larson; Maria Råstam; Henrik Anckarsäter; Christopher Gillberg; Thomas Nilsson; Sebastian Lundström
Journal:  BMC Psychiatry       Date:  2017-12-16       Impact factor: 3.630

8.  Prevalence and heritability of body dysmorphic symptoms in adolescents and young adults: a population-based nationwide twin study.

Authors:  Jesper Enander; Volen Z Ivanov; David Mataix-Cols; Ralf Kuja-Halkola; Brjánn Ljótsson; Sebastian Lundström; Ana Pérez-Vigil; Benedetta Monzani; Paul Lichtenstein; Christian Rück
Journal:  Psychol Med       Date:  2018-02-28       Impact factor: 7.723

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.